Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - Blood, 2004 - ashpublications.org
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
[HTML][HTML] Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - Blood, 2004 - Elsevier
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - BLOOD, 2004 - cris.unibo.it
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - Blood, 2003 - europepmc.org
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - BLOOD, 2004 - iris.unina.it
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
[引用][C] Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - BLOOD, 2004 - iris.unito.it
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia IRIS IRIS
Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie IT Italiano Italiano …
Home Sfoglia Macrotipologie & tipologie Autore Titolo Riviste Serie IT Italiano Italiano …
[PDF][PDF] Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - BLOOD, 2004 - Citeseer
The introduction of imatinib may lead to a substantial revolution of the management of
Philadelphia-positive (Ph) chronic myeloid leukemia (CML). Imatinib was rationally and …
Philadelphia-positive (Ph) chronic myeloid leukemia (CML). Imatinib was rationally and …
[引用][C] Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G ROSTI, G MARTINELLI, G REGE CAMBRIN… - Blood, 2004 - pascal-francis.inist.fr
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia CNRS Inist
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Pascal-Francis CNRS Pascal and Francis Bibliographic Databases Simple search Advanced …
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
G Rosti, G Martinelli, S Bassi, M Amabile… - …, 2004 - pubmed.ncbi.nlm.nih.gov
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
Molecular response to imatinib in late chronic-phase chronic myeloid leukemia.
G Rosti, G Martinelli, S Bassi, M Amabile, E Trabacchi… - BLOOD, 2004 - research.unipg.it
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …
remissions in patients with chronic myeloid leukemia (CML). In these patients measuring …